@SyngeneIntl #Syngene #Q3marketupdates
Q3fy21/20 in mn
Rev 5845 /5191
Ebidta 1933 /1735
PAT 1022 /918
9months fy21 /20
Rev 15257/14046
Ebidta 5026/4749
PAT 2443 /2460
Q3fy20 had exceptional gain of 459 mn leading to higher PAT
Good show
High conviction bet
Doubler for me
Q3fy21/20 in mn
Rev 5845 /5191
Ebidta 1933 /1735
PAT 1022 /918
9months fy21 /20
Rev 15257/14046
Ebidta 5026/4749
PAT 2443 /2460
Q3fy20 had exceptional gain of 459 mn leading to higher PAT
Good show
High conviction bet
Doubler for me
#Q3investorpresentations
Collaborated Deerfield discovery & development 3DC to advance integrated drug discovery projects, early target validation to preclinical evaluation
Expanded research facility Genome valley Hyderabad, +90 scientist
Accreditatn NABL fr medical devices
Collaborated Deerfield discovery & development 3DC to advance integrated drug discovery projects, early target validation to preclinical evaluation
Expanded research facility Genome valley Hyderabad, +90 scientist
Accreditatn NABL fr medical devices
Setup new RT-PCR testing facility approved by NABL & ICMR
360clients
20395 mn Rev Fy20
8 Collaborations with top 10 pharma companies
4200 + scientists
3662 mn PAT fy20
400+ patents ( held with clients )
31541 mn capex Mar 20
Integrated services- drug discovery,development,mfg
360clients
20395 mn Rev Fy20
8 Collaborations with top 10 pharma companies
4200 + scientists
3662 mn PAT fy20
400+ patents ( held with clients )
31541 mn capex Mar 20
Integrated services- drug discovery,development,mfg
Global CRO - Integrated Drug Discovery,Development,Mfg service provider
Small & Large Molecules,ADCs,Oligonucleotides
USFDA,EMA,PMDA approved,GLP Certified,AAALAC Accredited facility
IP assigned to clients
Strong track record of Data Integrity ,Security
Small & Large Molecules,ADCs,Oligonucleotides
USFDA,EMA,PMDA approved,GLP Certified,AAALAC Accredited facility
IP assigned to clients
Strong track record of Data Integrity ,Security
Moving from CRO to CRAMS with commercial manufacturing-“Follow the molecule” by expanding into commercialisation
Capacity Expansion - FTE services,mfng, formulation, biologics,stability
Capability Additions- viral testing, Oligonucleotide bioinformatics
New platforms: siRNA,ADC
Capacity Expansion - FTE services,mfng, formulation, biologics,stability
Capability Additions- viral testing, Oligonucleotide bioinformatics
New platforms: siRNA,ADC
Small molecules : cGMP facility to mft new chemical entities (NCEs)
Designed to support multigram to 100s of kgs/ batch of Intermediates and APIs for clinical trials
New greenfield investments done in Mangaluru(API plant to gen revs)to support larger commercial scale requirements
Designed to support multigram to 100s of kgs/ batch of Intermediates and APIs for clinical trials
New greenfield investments done in Mangaluru(API plant to gen revs)to support larger commercial scale requirements
Biologics : Mammalian & Microbial capabilities
Can support early stage, late stage and commercial launch supply requirements in mammalian
Capacities to support large volumes for late stage clinical requirements
R&D Expansion: Genome Valley, Hyderabad, commenced operation Aug 19
Can support early stage, late stage and commercial launch supply requirements in mammalian
Capacities to support large volumes for late stage clinical requirements
R&D Expansion: Genome Valley, Hyderabad, commenced operation Aug 19
API Mfg Expansion: Commercial Manufacturing to support product launch in Mangaluru, India -Commenced operation in March 2020; Capacity: 68KL ; Reactor size: 2-12KL
5,000 strong pool of employees
60,000 hrs training per year
4200 scientists
5,000 strong pool of employees
60,000 hrs training per year
4200 scientists
Offering funding for Ph.D. studies of eligible employees
Ph.D. programme launched in partnership with Merck KgaA and Institute of Bioinformatics and AppliedBiotechnology
Ranked as one of the 25 fastest growing companies in India by Outlook Business
Ph.D. programme launched in partnership with Merck KgaA and Institute of Bioinformatics and AppliedBiotechnology
Ranked as one of the 25 fastest growing companies in India by Outlook Business
India Pharma Award 2019 -For “Excellence in Contract Research and Manufacturing Services” at CPhI & P-MEC India Expo
71% promoter & promoter group holding
Unroll
@threadreaderapp
Compile
@threader_app
71% promoter & promoter group holding
Unroll
@threadreaderapp
Compile
@threader_app
• • •
Missing some Tweet in this thread? You can try to
force a refresh
